AHL
IKT icon

Abel Hall LLC’s Inhibikase Therapeutics IKT Stock Holding History

Abel Hall LLC’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.1K Buy
46,352
+31,789
+218% +$56.9K 0.02% 843
2026
Q1 		$24.5K Buy
+14,563
New +$25.9K 0.01% 786

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Abel Hall LLC's IKT Position: Q2 2026 in Review

Abel Hall LLC increased its Inhibikase Therapeutics (IKT) stake by 218% in Q2 2026, buying an estimated $56.9K and bringing the position to 46,352 shares worth $94.1K. The position accounts for 0.02% of the portfolio, ranked #843.

Abel Hall LLC first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Abel Hall LLC held 46,352 shares of Inhibikase Therapeutics worth $94.1K as of Q2 2026.
  • Abel Hall LLC bought 31,789 Inhibikase Therapeutics shares in Q2 2026, an estimated $56.9K.
  • Inhibikase Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #843 holding.
  • Abel Hall LLC first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.